Beta-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease

Journal of the American College of Cardiology

Volumn 64, Issue 3, 2014, Pages 247-252

  Andersson, Charlotte ^a   Shilane, David ^b   Go, Alan S ^c   Chang, Tara I ^b   Kazi, Dhruv ^d   Solomon, Matthew D ^c   Boothroyd, Derek B ^b   Hlatky, Mark A ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DIVISION OF RESEARCH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

beta adrenergic blocking agents; beta blockers; comparative effectiveness research; outcomes research; treatment effectiveness

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE; ARTICLE; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEX DIFFERENCE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ACUTE CORONARY SYNDROME; BLEEDING; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CHRONIC LUNG DISEASE; CORONARY ARTERY RECANALIZATION; DIABETES MELLITUS; DRUG FATALITY; ELECTRONIC MEDICAL RECORD; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HYPERTENSION; INCIDENCE; LIVER DISEASE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ONSET AGE; PROPORTIONAL HAZARDS MODEL; SIDE EFFECT; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS;

BETA-ADRENERGIC BLOCKING AGENTS; BETA-BLOCKERS; COMPARATIVE EFFECTIVENESS RESEARCH; OUTCOMES RESEARCH; TREATMENT EFFECTIVENESS;

ADRENERGIC BETA-ANTAGONISTS; AGED; CORONARY DISEASE; ELECTRONIC HEALTH RECORDS; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84904538588     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.04.042     Document Type: Article

References (22)

1. The CIBIS-II Investigators The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial Lancet 353 1999 9 13
2. The MERIT-HF Study Group Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353 1999 2001 2007
3. H.J. Dargie Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial Lancet 357 2001 1385 1390
4. A. Hjalmarson, D. Elmfeldt, and J. Herlitz et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial Lancet 2 1981 823 827
5. M. Packer, M.B. Fowler, E.B. Roecher Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study Circulation 106 2002 2194 2199
6. P.A. Heidenreich, K.M. McDonald, and T. Hastie et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina JAMA 281 1999 1927 1936
7. H.L. Huang, and K.A.A. Fox The impact of beta-blockers on mortality in stable angina: a meta-analysis Scott Med J 57 2012 69 75
8. S. Bangalore, G. Steg, and P. Deedwania et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease JAMA 308 2012 1340 1349
9. L.H. Lindholm, B. Carlberg, and O. Samuelsson Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis Lancet 366 2005 1545 1553
10. C.J. Pepine, E.M. Handberg, R.M. Cooper-DeHoff INVEST Investigators A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial JAMA 290 2003 2805 2816
11. C. Andersson, C. Mérie, and M. Jørgensen et al. Association of β-blocker therapy on the risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a Danish nationwide cohort study JAMA Intern Med 174 2014 336 344
12. M.A. Hlatky, M.D. Solomon, D. Shilane, T.K. Leong, R. Brindis, and A.S. Go Use of medications for secondary prevention after coronary bypass surgery compared with percutaneous coronary intervention J Am Coll Cardiol 61 2013 295 301
13. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 2004 1296 1305
14. K.M. Fox, D. Mulcahy, I. Findlay, I. Ford, and H.J. Dargie The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group Eur Heart J 17 1996 96 103
15. T. von Arnim Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. The TIBBS Investigators J Am Coll Cardiol 25 1995 231 238
16. N. Freemantle, J. Cleland, P. Young, J. Mason, and J. Harrison β-Blockade after myocardial infarction: systematic review and meta regression analysis BMJ 318 1999 1730 1737
17. S. Chatterjee, G. Biondi-Zoccai, and A. Abbate et al. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis BMJ 346 2013 f55
18. S.D. Fihn, J.M. Gardin, J. Abrams American College of Cardiology Foundation/American Heart Association Task Force 2012 ACCF/AHA/ACP/AATS/PCNA/ SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons J Am Coll Cardiol 60 2012 e44 e164
19. D. Nakatani, Y. Sakata, S. Suna Osaka Acute Coronary Insufficiency Study (OACIS) Investigators Impact of beta blockade therapy on long-term mortality after ST-segment elevation acute myocardial infarction in the percutaneous coronary intervention era Am J Cardiol 111 2013 457 464
20. P.K. Lindenauer, P. Pekow, K. Wang, D.K. Mamidi, B. Gutierrez, and E.M. Benjamin Perioperative beta-blocker therapy and mortality after major noncardiac surgery N Engl J Med 353 2005 349 361
21. M.J. London, K. Hur, G.G. Schwartz, and W.G. Henderson Association of perioperative β-blockade with mortality and cardiovascular morbidity following major noncardiac surgery JAMA 309 2013 1704 1713
22. Z.M. Chen, H.C. Pan, Y.P. Chen COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 366 2005 1622 1632